Longevity science has long suffered from an ambiguous reputation, filled with speculative promises, funded by Silicon Valley billionaires, and subject to hard-to-reproduce announcements. The year 2026 marks a turning point. Several clinical trials are reaching interim readouts, two bona fide gene therapies targeting aging markers have entered Phase II, and the scientific community is converging – cautiously – on a common conceptual framework: the revised hallmarks of aging from 2023 by Carlos López-Otín and his co-authors.

The Twelve Hallmarks and Drug Targets

The dominant conceptual framework identifies a dozen interconnected biological mechanisms of aging: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, intestinal dysbiosis, chronic inflammation, and loss of macroautophagy. The therapeutic strategy involves simultaneously targeting several of these hallmarks.

Four families of molecules are currently the focus of clinical efforts: senolytics (dasatinib + quercetin, fisetin) which eliminate senescent cells; calorie restriction mimetics (metformin, rapamycin, AMPK agonists); NAD+ boosters (NMN, NR); and partial reprogramming agents inspired by Yamanaka factors, whose early animal trials have produced spectacular results but raise significant oncological safety concerns.

Key Longevity Figures for 2026

  • 83.1 years: life expectancy at birth in France (women, 2025).
  • 77.3 years: life expectancy at birth in France (men, 2025).
  • 64.2 years: healthy life expectancy in France, up 0.8 years since 2020.
  • $27 billion: global investments in longevity biotech in 2025 (Longevity Investors Index).
  • 3,000+: active clinical trials concerning aging or age-related diseases (clinicaltrials.gov).
  • TAME: pivotal trial on metformin for prevention, initial partial results expected in 2026-2027.
  • 120 years: documented maximum human life span (Jeanne Calment, 122 years in 1997).

Three Companies to Watch — and Their Limitations

Altos Labs, founded in 2022 with initial funding of $3 billion (Jeff Bezos, Yuri Milner, Saudi PIF), has positioned itself on partial cellular reprogramming. Its laboratories in Cambridge, San Diego, and San Francisco employ some of the leading researchers in the field, including Juan Carlos Izpisua Belmonte and Shinya Yamanaka. The first clinical candidate is expected in 2027-2028.

Calico Life Sciences, an Alphabet subsidiary created in 2013 and long perceived as secretive, has refocused its strategy on two axes: age-related neurodegenerative diseases and stem cell regulation. Its collaboration with AbbVie has yielded several Phase I candidates.

Unity Biotechnology, a pioneer in senolytics, has faced several clinical setbacks (UBX0101 in osteoarthritis, UBX1325 in ophthalmology with partially disappointing Phase II results in 2023). The Unity case recalls a difficult truth: the hallmarks of aging are not equivalent to the clinical pathologies we know how to treat, and the translation from cell biology to human medicine remains slower than hoped.

Metformin as a Public Test

The TAME (Targeting Aging with Metformin) trial, led by Nir Barzilai at the Albert Einstein College of Medicine, has become emblematic. It is the first large-scale trial aiming to demonstrate that an existing molecule – metformin, a generic, inexpensive antidiabetic drug used for over sixty years – can delay the onset of several age-related diseases. The partial results expected in 2026-2027 will partly condition the regulatory trajectory of a potential first *aging drug* labeled as such by the FDA – a prospect that would ultimately require the FDA to recognize aging as a legitimate therapeutic indication.

> "We are not promising immortality. We are working to make an 80-year-old in 2050 have the functional vitality of a 65-year-old today. That is already huge." — *Nir Barzilai, Albert Einstein College of Medicine, TED MD conference, 2025.*

Key Takeaways

  • Dominant framework: the 12 hallmarks of aging (López-Otín et al., 2023).
  • Four families of molecules in clinical trials: senolytics, calorie restriction mimetics, NAD+ boosters, partial reprogrammers.
  • TAME: pivotal trial on metformin, partial results 2026-2027.
  • Altos Labs, Calico, Unity: three distinct industrial trajectories, highly unequal successes.
  • $27 billion invested in longevity biotech in 2025.
  • Central regulatory issue: FDA recognition of aging as an indication.